BRCA1 and ovarian cancer: It remains to be clarified whether olaparib also confers an advantage over standard chemotherapy in ovarian cancer, given that one clinical trial in advanced ovarian cancer patients with BRCA1/2 mutations whose disease had progressed or recurred after the use of platinum-based chemotherapy showed that the effect of olaparib was not superior to pegylated liposomal doxorubicin (PLD) (Kaye et al. 2012).